A Multi-Center, Randomized, Open-Label, Parallel Group Study With LJPC-401 for the Treatment of Myocardial Iron Overload in Adult Patients With Transfusion-Dependent Beta Thalassemia
Phase of Trial: Phase II
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Hepcidin (Primary)
- Indications Iron overload
- Focus Registrational; Therapeutic Use
- Sponsors La Jolla Pharmaceutical Company
- 22 Feb 2018 According to a La Jolla Pharmaceutical Company media release, the company anticipate filing a market authorization application (MAA) for LJPC-401 in Europe, subjects to the positive data from this trial.
- 04 Dec 2017 Status changed from planning to recruiting according to a La Jolla Pharmaceutical Company media release.
- 22 Sep 2016 New trial record